.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Cipla
US Department of Justice
Daiichi Sankyo
Moodys
Farmers Insurance
Baxter
Medtronic
Cerilliant

Generated: December 18, 2017

DrugPatentWatch Database Preview

OXYTROL Drug Profile

« Back to Dashboard

Which patents cover Oxytrol, and when can generic versions of Oxytrol launch?

Oxytrol is a drug marketed by Allergan Sales Llc and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in twenty countries.

The generic ingredient in OXYTROL is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeYY► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► Subscribe► Subscribe
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003ABRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan Sales LlcOXYTROL FOR WOMENoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OXYTROL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003► Subscribe► Subscribe
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003► Subscribe► Subscribe
Allergan Sales LlcOXYTROLoxybutyninFILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for OXYTROL

Drugname Dosage Strength RLD Submissiondate
oxybutyninTransdermal System Extended-re3.9 mg/24 hrsOxytrol8/19/2008

Non-Orange Book Patents for Tradename: OXYTROL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,029,694Compositions and methods for transdermal oxybutynin therapy► Subscribe
8,241,662Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy► Subscribe
7,087,241Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OXYTROL

Country Document Number Estimated Expiration
Spain2532495► Subscribe
European Patent Office1992342► Subscribe
Canada2718277► Subscribe
China101305994► Subscribe
MexicoPA05004110► Subscribe
Japan2013082720► Subscribe
European Patent Office1280486► Subscribe
Japan2017031191► Subscribe
South Korea20050061588► Subscribe
New Zealand539562► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Accenture
US Department of Justice
Moodys
Cerilliant
Argus Health
Cantor Fitzgerald
Boehringer Ingelheim
Fish and Richardson
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot